2.96 USD
▼-0.22-6.92%
盘后 2.77 -6.42%
2026-11-20
市值
$5.34M
市盈率
—
EPS
-9.23
股息率
—
52 周区间
2.87 – 23.60
成交量
39.69K
Beta
0.83
目标价
—
52W 低 2.8752W 高 23.60
价格走势
公司简介
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product cand...